Pooled Human Plasma Apheresis Derived from Innovative Research was used in the following study:
Miguel Alcaide, Matthew Cheung, Jack Hillman, S. Rod Rassekh, Rebecca J. Deyell, Gerald Batist, Aly Karsan, Alexander W. Wyatt, Nathalie Johnson, David W. Scott & Ryan D. Morin
Scientific Reports
July 28, 2020
Since their initial description in 1948, small DNA fragments travelling outside the cells in internal bodily fluids and excretions have revolutionized numerous fields in public health and preventive medicine. Cell-free DNA (cfDNA) is generally thought to arise from cellular breakdown mechanisms combined with active release from living cells.
cfDNA has become a popular biomarker in the fields of non-invasive cancer detection and monitoring, organ transplantation, prenatal genetic testing and pathogen detection. However, while cfDNA samples can be obtained using a broad variety of methods, there is an urgent need to standardize analytical tools aimed at assessing its basic properties.
Typical methods to determine the yield and fragment size distribution of cfDNA samples are usually either blind to genomic DNA contamination or the presence of enzymatic inhibitors, which can confound and undermine downstream analyses. Scientists in this study developed a novel assay that successfully generated five distinct fluorescence clusters, which were observed in 2D fluorescence plots.
Related products available from Innovative Research also include:
Single Donor Human Whole Blood
